{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:53Z","timestamp":1792173473973,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY021574"],"award-info":[{"award-number":["R01EY021574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004286","name":"Santen Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["EY002162"],"award-info":[{"award-number":["EY002162"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jconrel.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T23:07:46Z","timestamp":1510096066000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-5302","authenticated-orcid":false,"given":"Jean","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kudisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Rosa Konichi","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Aya-Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele M.","family":"Bloomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Mudumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Bhisitkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal A.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.11.008_bb0005","series-title":"Shields' Textbook of Glaucoma","author":"Allingham","year":"2010"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0010","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","article-title":"Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial","volume":"114","author":"Bengtsson","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","author":"Gaasterland","year":"2000","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","article-title":"Adherence with topical glaucoma medication monitored electronically. The travatan dosing aid study","volume":"116","author":"Okeke","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0420.2007.00882.x","article-title":"Use of eyedrops in glaucoma: How can we help to reduce non-compliance?","volume":"85","author":"Chawla","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0040","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","article-title":"The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity","volume":"118","author":"Sleath","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201600780","article-title":"Long-term subconjunctival delivery of brimonidine tartrate for glaucoma treatment using a microspheres\/carrier system","author":"Pek","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2015.10.027","article-title":"Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug","volume":"220","author":"Park","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0060","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1167\/iovs.16-19585","article-title":"Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma","volume":"57","author":"Kim","year":"2016","journal-title":"Investig. Opthalmology Vis. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2017.11.008_bb0065","first-page":"5709","volume":"56","author":"Kirihara","year":"2015","journal-title":"Investig. Opthalmology Vis. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2017.11.008_bb0070","first-page":"5708","article-title":"Safety and efficacy of DE-117, a selective EP2 agonist in a phase 2a study","volume":"56","author":"Ihekoromadu","year":"2015","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jop.2012.0152","article-title":"Ocular biocompatibility and structural integrity of micro- and nanostructured poly(caprolactone) films","volume":"29","author":"Bernards","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0080","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1167\/iovs.12-10393","article-title":"Acceptance, attitudes, and beliefs of singaporean Chinese toward an ocular implant for glaucoma drug delivery","volume":"53","author":"Foo","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0085","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/IJG.0000000000000197","article-title":"A survey on the preference of sustained glaucoma drug delivery systems by singaporean Chinese patients: A comparison between subconjunctival, intracameral, and punctal plug routes","volume":"24","author":"Chan","year":"2015","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0090","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1167\/iovs.15-17757","article-title":"In vitro and in vivo sustained zero-order delivery of rapamycin (sirolimus) from a biodegradable intraocular device","volume":"56","author":"Lance","year":"2015","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0095","unstructured":"Allergan. Safety and efficacy of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. ClinicalTrials.gov. <https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02250651?term=NCT02250651&rank=1>"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0100","unstructured":"Envisia Therapeutics. Safety and efficacy of ENV515 travoprost extended release (XR) in patients with bilateral ocular hypertension or primary open angle glaucoma. ClinicalTrials.gov. <https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02371746?term=NCT02371746&rank=1>"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0105","series-title":"Glaucoma: Basic and clinical concepts","author":"Rumelt","year":"2011"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0110","first-page":"5319","article-title":"In vitro hydrolysis of latanoprost by human ocular tissues","author":"Guerra","year":"2012","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","article-title":"Intraocular pressure fluctuation. A risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study","volume":"115","author":"Caprioli","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study","volume":"120","author":"Kass","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0130","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","article-title":"Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics","volume":"58","author":"Mannermaa","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(90)90215-P","article-title":"Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits","volume":"61","author":"Urtti","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","article-title":"Corneal and conjunctival changes caused by commonly used glaucoma medications","volume":"23","author":"Noecker","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11588830-000000000-00000","article-title":"Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue","volume":"28","author":"Servat","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2017.11.008_bb0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00055735-199604000-00014","article-title":"Side effects of antiglaucomatous drugs on the ocular surface","volume":"7","author":"Baudouin","year":"1996","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0155","doi-asserted-by":"crossref","first-page":"25003","DOI":"10.1088\/1748-6041\/6\/2\/025003","article-title":"A poly(\u03b5-caprolactone) device for sustained release of an anti-glaucoma drug","volume":"6","author":"Natu","year":"2011","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0160","first-page":"597","article-title":"Regenerative capacity of the corneal endothelium in rabbit and cat","volume":"16","author":"Van Horn","year":"1977","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"10.1016\/j.jconrel.2017.11.008_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-4835(75)90076-7","article-title":"Endothelial wound repair in primate cornea","volume":"21","author":"Van Horn","year":"1975","journal-title":"Exp. Eye Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T04:37:34Z","timestamp":1537850254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917309781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":33,"alternative-id":["S0168365917309781"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.008","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}